Qualigen Therapeutics Valuation
| QLGN Stock | USD 3.76 0.14 3.59% |
At this time, the company appears to be undervalued. Qualigen Therapeutics holds a recent Real Value of $12.78 per share. The prevailing price of the company is $3.76. Our model determines the value of Qualigen Therapeutics from analyzing the company fundamentals such as Shares Outstanding of 736.43 K, shares owned by institutions of 1.77 %, and Return On Equity of -8.42 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Qualigen Therapeutics' valuation include:
Price Book 0.4055 | Enterprise Value 2.4 M | Enterprise Value Ebitda (0.05) | Price Sales 0.3869 | Trailing PE 0.0011 |
Undervalued
Today
Please note that Qualigen Therapeutics' price fluctuation is slightly risky at this time. Calculation of the real value of Qualigen Therapeutics is based on 3 months time horizon. Increasing Qualigen Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Qualigen Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Qualigen Stock. However, Qualigen Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.76 | Real 12.78 | Target 40.0 | Hype 3.38 |
The intrinsic value of Qualigen Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Qualigen Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Qualigen Therapeutics helps investors to forecast how Qualigen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Qualigen Therapeutics more accurately as focusing exclusively on Qualigen Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Qualigen Therapeutics' intrinsic value based on its ongoing forecasts of Qualigen Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Qualigen Therapeutics' closest peers.
Qualigen Therapeutics Cash |
|
Qualigen Valuation Trend
Knowing Qualigen Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Qualigen Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Qualigen Therapeutics Total Value Analysis
Qualigen Therapeutics is at this time forecasted to have valuation of 2.43 M with market capitalization of 2.87 M, debt of 1.3 M, and cash on hands of 6.62 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Qualigen Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.43 M | 2.87 M | 1.3 M | 6.62 M |
Qualigen Therapeutics Investor Information
The company has price-to-book ratio of 0.41. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Qualigen Therapeutics recorded earning per share (EPS) of 3504.51. The entity last dividend was issued on the 26th of May 2020. The firm had 1:50 split on the 5th of November 2024. Based on the key indicators related to Qualigen Therapeutics' liquidity, profitability, solvency, and operating efficiency, Qualigen Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Qualigen Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Qualigen Therapeutics has an asset utilization ratio of 255.98 percent. This suggests that the Company is making $2.56 for each dollar of assets. An increasing asset utilization means that Qualigen Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Qualigen Therapeutics Ownership Allocation
Qualigen Therapeutics holds 3.77 pct. of its outstanding shares held by insiders and 1.77 pct. owned by third-party entities.Qualigen Therapeutics Profitability Analysis
The company reported the previous year's revenue of 5.2 M. Net Loss for the year was (12.48 M) with profit before overhead, payroll, taxes, and interest of 680.8 K.About Qualigen Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Qualigen Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Qualigen Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Qualigen Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Qualigen Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Qualigen Therapeutics. We calculate exposure to Qualigen Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Qualigen Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -4.5 K | -4.7 K | |
| Pretax Profit Margin | (2.40) | (2.52) | |
| Operating Profit Margin | (2.17) | (2.28) | |
| Net Loss | (2.58) | (2.71) |
Qualigen Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 5.1 M |
Qualigen Therapeutics Current Valuation Indicators
Qualigen Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Qualigen Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Qualigen Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Qualigen Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Qualigen Therapeutics' worth.When determining whether Qualigen Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Qualigen Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Qualigen Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Qualigen Therapeutics Stock: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Qualigen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Qualigen Stock, please use our How to Invest in Qualigen Therapeutics guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Qualigen Therapeutics. If investors know Qualigen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Qualigen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 3.5 K | Revenue Per Share 1.034 | Quarterly Revenue Growth 0.137 | Return On Assets (0.75) | Return On Equity (8.42) |
The market value of Qualigen Therapeutics is measured differently than its book value, which is the value of Qualigen that is recorded on the company's balance sheet. Investors also form their own opinion of Qualigen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Qualigen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Qualigen Therapeutics' market value can be influenced by many factors that don't directly affect Qualigen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Qualigen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Qualigen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Qualigen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.